Johnson & Johnson upgrade from Leerink, shares in S&P 500 focus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:11.

Johnson & Johnson (US4781601046) draws renewed analyst attention after an upgrade from Leerink Partners. The Wall Street firm now rates the S&P 500 healthcare heavyweight Outperform with a 265 dollar price target, adding a fresh impulse for the NYSE-listed shares.

What Leerink Partners changed

Leerink Partners analyst David Risinger upgraded Johnson & Johnson from Market Perform to Outperform, setting a 265 dollar price target according to a recent market summary of analyst actions. TrendSpider compiles the Leerink rating and target. The move puts Leerink in the bullish camp on the NYSE-listed blue chip.

The new 265 dollar target implies moderate upside from a spot level around 231 dollars per share, based on late Monday trading data. The upgrade comes against a backdrop of robust year-to-date performance, with Johnson & Johnson stock up double digits in 2026 in some analyst roundups, underpinned by steady demand in pharmaceuticals and MedTech.

How consensus on J&J looks now

Across the broader analyst community, Johnson & Johnson continues to attract a mix of Buy and Hold ratings from major houses that follow S&P 500 healthcare names. Aggregated data on one large broker platform show a clear majority of recommendations in the positive or neutral range, with only a small minority on the Sell side for JNJ. Fidelity’s factsheet underlines the defensive income profile.

The company’s long dividend track record remains a central point for income-focused investors. Johnson & Johnson is frequently cited in dividend research as a so-called Dividend Aristocrat, with more than six decades of consecutive annual dividend increases, a feature that often supports positive ratings in low-yield phases of the US Treasury market.

The products behind the stock

Johnson & Johnson generates revenue primarily through prescription medicines, MedTech devices and over-the-counter consumer health products. A well-known consumer brand from the historic portfolio is Tylenol, a pain reliever that has been sold in North America for decades alongside other everyday healthcare products.

Where the J&J shares trade today

The Johnson & Johnson shares (US4781601046) traded on the NYSE at 231.33 US dollars as of 2026-06-23, 00:59 EDT, according to a large broker quote service.

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.